INS and obesity disorder: GLP-1 is released after food intake and acts to amplify glucose-dependent insulin secretion, and it has been in the spotlight as a target for the treatment of obesity and diabetes as its positive effects on glucose homeostasis, appetite regulation, gastric emptying and postprandial lipid metabolism (26, 27).